权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Functional characterization of SARS-CoV-2 myeloid cell receptors as an immunopathogenic mechanisms of COVID-19

SARS-CoV-2 骨髓细胞受体作为 COVID-19 免疫致病机制的功能特征

基本信息

批准号：
10443833
负责人：
JUN WANG
金额：
$ 21.19万
依托单位：
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-07-02 至 2023-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10443833
关键词：
2019-nCoV ACE2 Acute Respiratory Distress Syndrome Address Affect Affinity B-Lymphocytes Binding C-Type Lectins CD209 gene COVID-19 COVID-19 pandemic COVID-19 pathogenesis COVID-19 patient COVID-19 prevention COVID-19 severity COVID-19 treatment Cell Communication Cell Line Cells Coculture Techniques Collaborations Critical Pathways Data Data Set Dendritic Cells Disease Ectopic Expression Epithelial Cells Epitopes Family member Human Hyperactivity Immune Immune response Immune system Immunity Individual Infection Inflammation Inflammatory Response Lead Lectin Ligands Ligation Lung Lymphopenia Mediating Meta-Analysis Molecular Profiling Myeloid Cells New York Pathogenesis Pathogenicity Pathologic Pathway interactions Pattern Phenotype Play Polysaccharides Population Proteins Public Health Publishing Receptor Cell Receptor Signaling Role SARS-CoV-2 spike protein System T-Lymphocyte Testing Therapeutic Therapeutic antibodies Tissues Universities Viral Viral Pathogenesis Virus Virus Diseases Virus Receptors adaptive immunity base chemokine cytokine cytokine release syndrome experience experimental study functional outcomes immunopathology immunoregulation improved knock-down macrophage medical schools monocyte nanobodies new therapeutic target novel novel virus overexpression pandemic disease programs receptor receptor binding receptor expression response single cell sequencing single-cell RNA sequencing targeted treatment transcriptome sequencing

项目摘要

Project Summary The rapid spread of SARS-CoV-2 and the resulting Coronavirus Disease 2019 (COVID-19) pose a global pandemic. SARS-CoV-2 and its family members share some puzzling, unique pathological features, most notably acute respiratory distress syndrome (ARDS), cytokine release syndrome (CRS), and lymphopenia, despite excessive myeloid cell–dominant inflammation, which has been correlated with COVID-19 severity. How the virus engages and dysregulates the immune system is currently unknown; although angiotensin-converting enzyme 2 (ACE2) is the canonical SARS-CoV-2 receptor, immune cells, particularly myeloid cells, express little, if any, levels of ACE2 despite evidence for direct viral engagement. Based on our extensive experience in the discovery and characterization of immune-modulatory receptor-ligand interactions, we sought to address how SARS-CoV-2 interacts with myeloid cells, which play essential roles in both virus innate sensing and the modulation of host immunity, by developing a myeloid cell receptor-focused ectopic expression screen. In ongoing experiments, we have identified several novel glycan-dependent host interaction partners for SARS-CoV-2 Spike (S) protein, including several C-type lectins and Tweety Family Member 2 (TTYH2). Pulmonary single-cell RNA sequencing (scRNA-seq) analysis in COVID-19 patients indicates a myeloid cell-dominant expression of these receptors as opposed to ACE2. In the preliminary studies, we have shown that these molecules interact mostly through regions outside of the ACE2 receptor-binding domain (RBD), suggesting that they may provide a novel function outside of virus entry. Although these receptors do not support the active replication of authentic SARS-CoV-2, the direct virus-myeloid cell engagement induces a robust pro-inflammatory response, which is blocked by receptor-decoy proteins and a picomolar-affinity anti- spike bispecific nanobody that also blocks virus infection through ACE2. Together, our findings provide the first evidence for direct immune modulation by SARS-CoV-2, potentially targeted for therapeutic benefit. Given these findings, we hypothesize that novel SARS-CoV-2 virus-receptor interactions in myeloid cells constitute a pathogenic pathway for COVID-19, serving as signaling receptors that directly drive myeloid cell dysregulation. These new direct virus-immune interactions may also have heretofore unexplored functions to affect other cells indirectly. These hypotheses will be addressed within the following Specific Aims: (1) to determine the functional contribution of each myeloid cell receptor in the induction of pro-inflammatory responses upon SARS-CoV-2 engagement, and (2) to determine the role of these interactions in the dysregulation of adaptive immunity and SARS-CoV-2 trans-infection through ACE2 receptor. Our study on novel virus myeloid cell receptors that govern aberrant immune responses would greatly contribute to our understanding of COVID- 19 pathogenesis, revealing new therapeutic targets against COVID-19 for the benefit of humanity at large.

项目总结